相关实验视频

Updated: Sep 18, 2025

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Application of I TASSER, trRosetta, UCSF Chimera, HADDOCK server, and HEX loria for De Novo and In Silico Design of Proteins

Published on: July 8, 2025

基于结构的设计和评估针对人类和异酶的铁酶抑制剂

Salvatore Mirabile¹, Giovanna Pitasi¹, Sonia Floris²

¹Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina Viale F. Stagno D'Alcontres 31 I-98166 Messina Italy laura.deluca@unime.it.

RSC medicinal chemistry

|June 25, 2025

概括

研究人员开发了新的化合物来抑制皮肤色素增多的关键酶 - - 铁酶. 化合物2和3表现出强大的抑制人体氨酶 (hTYR) 和低毒性,为化品应用提供了潜力.

科学领域:

生物化学生物化学
药用化学医学化学

背景情况:

铁酶抑制对于治疗皮肤色素增多至关重要.
开发有效和安全的铁酶抑制剂是医药和化品领域的一个重大挑战.
之前的研究发现了一种化合物,MehT-3,有效对抗各种类型的氨酸酶.

研究的目的:

设计和合成基于MehT-3架构的新型铁酶抑制剂.
评估这些衍生物对Agaricus bisporus铁酶 (AbTYR) 和人类铁酶 (hTYR) 的抑制活性.
评估最有前途的化合物作为抗氧化剂和防晒成分的潜力.

主要方法:

预测化合物与AbTYR和hTYR腔体结合的 *in silico*.
简单而高效的合成方法来制备衍生品.
酶抑制试验以确定对AbTYR和hTYR的亲和值 (μM).
毒性和抗氧化活性评估.

主要成果:

合成了一系列聚焦的MehT-3衍生物.
确定了AbTYR和hTYR的强效抑制剂,其亲和度值在5.3至40.7μM之间.
化合物2和3表现出对hTYR的优越活性,低毒性和有效的抗氧化特性.

结论:

开发的化合物,特别是2和3,是治疗皮肤色素过高的有希望的候选物.
使用的计算协议对于开发新型铁酶抑制剂是有效的.
这些发现支持这些化合物在防晒等化品中的潜在用途.

更多相关视频

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Protein WISDOM: A Workbench for In silico De novo Design of BioMolecules

Published on: July 25, 2013

相关概念视频

Enzyme Inhibition

Enzyme Inhibition

Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.

Structure-Activity Relationships and Drug Design

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...